You are here: Urology Textbook > Kidneys > Nephrolithiasis
Medical and Surgical Treatment of Kidney and Ureteral Stones
- Nephrolithiasis: Etiology and Epidemiology
- Diagnosis of Nephrolithiasis and Renal Colic
- Treatment of Kidney and Ureteral Stones
![]() |
Renal Colic
Acute pain medication:
NSAIDs (diclofenac or metamizole) are first-line medications. If pain relief is inadequate or NSAIDs are contraindicated, opioids such as piritramide or morphine are recommended. Colic that cannot be controlled with medication is an indication for ureteral stenting. Intranasal desmopressin may be tried off-label; it promptly reduces diuresis and relieves pain. Further treatment depends on stone size and location; see the table Treatment options for urolithiasis. Butylscopolamine, which is frequently administered, has no relevant efficacy for renal colic and is not recommended.
- Diclofenac: 37.5 mg slowly IV (0.5 mg/kg in children). Maximum daily dose: 150 mg (2 mg/kg in children).
- Metamizole: 1–2 g IV as a short infusion over 15–30 min. Maximum daily dose: 6 g (70 mg/kg).
- Piritramide: 7.5 mg slowly IV. In children, 0.05–0.1 mg/kg IV. Repeat doses may be given after 6 h and should be administered subcutaneously.
- Morphine: 10 mg slowly IV (0.1 mg/kg in children). Repeat doses may be given after 4 h and should be administered subcutaneously.
Conservative Therapy – Medical Expulsive Therapy
Ureteral stones:
Ureteral stones < 5 mm have a 75 % chance of spontaneous passage. For stones ≥ 5 mm, the spontaneous passage rate falls to 62 %. The farther distally the stone is located, the more likely spontaneous passage becomes: passage rates are 49 %, 58 %, and 68 % for proximal, middle, and distal ureteral stones, respectively (Yallappa et al., 2018). Almost all stones that pass spontaneously do so within 6 weeks after symptom onset. Contraindications to conservative management include infected hydronephrosis, forniceal rupture, refractory colic, persistent urinary obstruction, and a low probability of spontaneous passage.
Medical expulsive therapy:
Patients managed conservatively should be counseled about the possibility of recurrent colic and prescribed medication for use as needed.
- Sufficient fluid intake and physical activity.
- Diclofenac 50 mg 1-0-1 as pain medication and against ureteral wall edema.
- For prevesical ureteral stones, off-label use of an α1A-blocker (tamsulosin or alfuzosin) may relieve pain and accelerate stone passage. Other medications reported to be effective but lacking approval or sufficient supporting evidence include nifedipine and Rowatinex.
- Additional pain medication as needed, such as metamizole 500–1000 mg orally.
- Anticholinergics (e.g., butylscopolamine) had no effect in several studies (Kallidonis et al., 2011).
Calyceal kidney stones:
Calyceal stones smaller than 5 mm that are likely to pass spontaneously do not require treatment. Stones ≥ 5 mm may also be monitored with regular follow-up if the patient prefers; invasive treatment is necessary if they grow substantially or cause symptoms. Observation is not appropriate for pilots, long-distance drivers, or people in comparable occupations. The clinical significance of small residual stones after ESWL is controversial; they are often managed conservatively. Comorbidities should be considered when deciding on treatment.
Treatment of Upper Urinary Tract Obstruction
Emergency indications:
Pain that cannot be controlled with medication, forniceal rupture, urinoma, infected hydronephrosis, urosepsis, or significant acute kidney injury.
Methods of decompression:
Options include retrograde placement of an MJ or DJ ureteral stent [fig. DJ placement] or percutaneous nephrostomy. If infection is present, definitive stone treatment should be delayed until the infection is controlled.
![]() |
Extracorporeal Shock Wave Lithotripsy (ESWL)
Indications:
ESWL is an option for renal calyceal and renal pelvic stones up to 2 cm in diameter and for selected ureteral stones; see the table Treatment options for urolithiasis.
Procedure and complications:
See section Extracorporeal Shock Wave Lithotripsy ESWL.
Results:
Averaged across all stone locations, approximately 73 % of patients are stone-free after 3 months. Prescribing medication to facilitate stone passage is important for treatment success because all fragments must pass through the ureter.
Calyceal kidney calculi:
Stone-free rates of up to 40–78 % can be achieved for lower-pole stones. Rates are somewhat higher for upper-pole stones, at 64–85 %. Clearance from the lower-pole calyces depends on the diameter and length of the calyceal necks and the angle between the ureter and the lower-pole calyces.
Calculi in renal pelvis and ureter:
Stone-free rates of up to 90 % can be achieved.
Predictors for a successful ESWL:
Stones in the upper and middle calyceal groups, stones with an irregular surface and heterogeneous internal structure, and struvite stones.
Predictors for unsuccessful ESWL:
Lower-pole stones, particularly when the angle between the ureter and lower-pole calyces is small; stones with a narrow (< 5 mm) and long (> 20 mm) calyceal neck; brushite or cystine stones; stones with a smooth surface and homogeneous internal structure; stone density over 970 HU; and a long skin-to-stone distance (> 10 cm).
Ureterorenoscopy (URS)
Indications:
Ureteral stones are the classic indication for ureterorenoscopy; see the table Treatment options for urolithiasis. Improvements in flexible instruments and intraluminal stone disintegration have made it possible to treat large renal stones as well (RIRS: retrograde intrarenal surgery). URS/RIRS is preferred in patients with obesity, anticoagulation, or pregnancy.
![]() |
Surgical technique and complications:
See section ureterorenoscopy. Small ureteral stones are extracted with a Dormia basket [fig. URS stone extraction] or forceps. Larger stones can be fragmented with mechanical lithotriptors or laser devices [fig. URS laser stone disintegration]. Proximal ureteral stones can also be pushed into the renal pelvis during URS and fragmented with ESWL (push and smash).
![]() |
![]() |
Results:
URS removes 90 % of distal and 60 % of proximal ureteral stones in a single session. With newer techniques (flexible URS with a holmium laser), stone-free rates over 90 % have been reported for proximal ureteral stones, depending on size.
Percutaneous Nephrolithotomy (PNL)
Percutaneous nephrolithotomy is an endoscopic, minimally invasive procedure for removing large kidney stones. Abbreviations: PCNL or PNL. Synonym: percutaneous nephrolitholapaxy. The introduction of smaller instruments (Mini-PNL) has reduced the morbidity of PNL.
Indications:
Large staghorn stones; renal pelvic and calyceal stones larger than 1.5 cm; lower-pole stones 10 mm or larger; calyceal stones with calyceal neck stenosis; and stones refractory to ESWL or URS.
Surgical technique and complications:
See the section on percutaneous nephrolithotomy (PNL).
Results:
Stone-free rates can be as high as 90 %, depending on the anatomy of the renal pelvis and calyces and the stone burden. Unlike lithotripsy with URS or ESWL, fragmented material is removed during the procedure.
Laparoscopic and Open Stone Surgery
Open, laparoscopic, or robotic stone surgery is uncommon and reserved for exceptional cases: very large or complex staghorn stones (nephrolithotomy); very large ureteral stones (ureterotomy); a concurrent anatomic repair (pyeloplasty); difficult anatomy (pelvic or horseshoe kidney); a nonfunctioning kidney (nephrectomy); or other situations not amenable to endoscopic treatment. Renal function must be assessed before stone removal.
Basic Measures of Stone Recurrence Prevention
Without the presence of risk factors [table risk factors for stone recurrence], the following basic measures are recommended to prevent the recurrence of nephrolithiasis (Siener et al., 2006):
Fluid intake:
Increase fluid intake to achieve a urine output of > 2.0 L. Spread fluid intake evenly throughout the day; drinking at night may be helpful for patients with frequent recurrences. Urine specific gravity should be below 1.010 g/ml.
Suitable drinks dilute urine without substantially changing its composition (electrolytes and pH): mineral water rich in magnesium and bicarbonate, tap water, herbal tea, and diluted fruit juices. Unsuitable drinks include sugary soft drinks, excessive coffee or black tea, and alcoholic beverages.
Diet:
Reduce animal protein intake and increase fruit, grains, and vegetables. Avoid oxalate-rich vegetables such as spinach, chard, and rhubarb. Do not restrict calcium intake; the target is 1000 mg of calcium per day. Avoid alcohol.
Body weight:
Obesity and associated dietary patterns are risk factors for recurrent nephrolithiasis. Aim for gradual, long-term weight reduction through the dietary changes described above, increased fluid intake, and physical activity. Fasting and restrictive diets are contraindicated.
Pharmacological Recurrence Prevention
Successful pharmacological prevention requires an accurate metabolic evaluation and patient adherence, including consistent implementation of the basic preventive measures described above. Frequent recurrences occur in 25 % of patients with stones. The table on risk factors for stone recurrence lists risk groups that may benefit from pharmacological prevention. Patients who have undergone interventional treatment may also benefit in terms of recurrence-free survival and spontaneous passage of residual fragments (Soyguer et al., 2002).
Calcium oxalate stones:
Alkali citrates, or sodium bicarbonate, prevent calcium oxalate stones. Both substances reduce citrate reabsorption in the proximal tubule and thus improve the inhibitory properties of the urine against stone formation. In the following specific metabolic constellations, additional medication is recommended (Straub et al., 2005) (EAU Guidelines):
- Urinary calcium excretion 5–8 mmol/d: Alkali citrates 9–12 g/d, or sodium bicarbonate 1.5 g 1-1-1 orally.
- Urinary calcium excretion > 8 mmol/d: Alkali citrates 9–12 g/d, or sodium bicarbonate 1.5 g 1-1-1 orally. Add a thiazide diuretic to reduce calciuria, such as hydrochlorothiazide 25 mg/d; increase to 50 mg/d if needed. The NOSTONE trial found no convincing benefit of hydrochlorothiazide over placebo (Dhayat et al., 2023); however, the EAU guidelines continue to recommend thiazides for hypercalciuria.
- Urinary citrate excretion < 2.5 mmol/d: Alkali citrates 9–12 g/d.
- Urinary oxalate excretion 0.5–1 mmol/d: A low-oxalate diet, calcium intake of approximately 1000 mg/d with meals, and magnesium intake of 200–400 mg/d with meals (not in kidney failure).
- Urinary oxalate excretion > 1 mmol/d: Primary hyperoxaluria is likely; treatment should be provided by a specialized center. Management includes high urine dilution, pyridoxine (vitamin B6), alkali citrates, and magnesium. In type 1 hyperoxaluria, lumasiran inhibits expression of a liver enzyme (glycolate oxidase) through RNA interference; it has been available as an orphan drug since 2020. Despite medical treatment, kidney failure may progress to the terminal stage, and combined liver and kidney transplantation may be required.
- Urinary uric acid excretion > 4 mmol/d: A low-purine diet, alkali citrates 9–12 g/d, and allopurinol 100 mg/d. Increase allopurinol to 300 mg/d when serum uric acid is above 380 μmol/L, depending on kidney function. Febuxostat is an alternative for patients with kidney failure.
- Urinary magnesium excretion < 3 mmol/d: Magnesium 200–400 mg/d with meals (not in kidney failure).
Calcium phosphate stones:
Causes include hyperparathyroidism, renal tubular acidosis, and urinary tract infection. See the next section for treatment of infection stones. Parathyroidectomy is the treatment of choice for hyperparathyroidism. For renal tubular acidosis, use alkali citrates 9–12 g/d or sodium bicarbonate 1.5 g 1-1-1 orally. Add a calcium-sparing diuretic such as hydrochlorothiazide 25 mg/d when urinary calcium excretion is above 8 mmol/24 h; increase to 50 mg/d if needed.
For calcium phosphate stones with persistently alkaline urine, urine acidification with L-methionine 200–500 mg 1-1-1 may be considered after urinary tract infection, hyperparathyroidism, and renal tubular acidosis have been excluded (target urine pH 5.8–6.2). Note: L-methionine is contraindicated in renal tubular acidosis.
Infection stones:
Persistently alkaline urine (pH > 7) on a 24-hour urine pH profile is a key finding. Successful treatment depends on complete stone removal, appropriate long-term antibiotic therapy, and urinary dilution. For recurrence prevention, urine acidification with L-methionine 200–500 mg 1-1-1 may help (target urine pH 5.8–6.2).
Uric acid stones:
The main causes are hyperuricosuria and persistently acidic urine (pH below 6). Prevention centers on a low-purine diet, urinary dilution, and urine alkalinization with alkali citrates or sodium bicarbonate (target urine pH 6.2–6.8). For chemolysis of uric acid stones, target a urine pH of 7.0–7.2. Allopurinol 100 mg/d can reduce hyperuricosuria; increase to 300 mg/d when serum uric acid is above 380 μmol/L, depending on kidney function. Febuxostat is an alternative for patients with kidney failure.
Cystine stones:
Increase urine output to > 3.5 L in adults and alkalinize urine with alkali citrates (target pH 7.5). Reduce sodium and animal protein intake. If cystine excretion remains above 3 mmol/d despite these measures, oral tiopronin is indicated. Start with 250 mg 1-0-1; the dose may be increased to 2 g/d.
Xanthine or 2,8-dihydroxyadenine stones:
Increase urinary dilution and follow a low-purine diet. Consider allopurinol for 2,8-dihydroxyadenine stones.
| Renal colic | Index | Oncocytoma |
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
References
Coe u.a. 2005 COE, F. L. ; EVAN, A. ;
WORCESTER, E.:
Kidney stone disease.
In: J Clin Invest
115 (2005), Nr. 10, S. 2598–608
Dhayat, N. A. et al. Hydrochlorothiazide and Prevention of Kidney-Stone Recurrence. N Engl J Med 2023;388(9):781–791. doi: 10.1056/NEJMoa2209275.
Kallidonis, P.; Liourdi, D. & Liatsikos, E.
Medical
treatment for renal colic and stone expulsion
Eur Urol Suppl, 2011,
10, 415-422.
Moe 2006 MOE, O. W.:
Kidney stones: pathophysiology and medical management.
In: Lancet
367 (2006), Nr. 9507, S. 333–44
R. Siener und A. Hesse.
[modern general metaphylaxis of stone disease. new risks, new
evidence, new recommendations].
Urologe A, 45 (11): 1392, 1394–1392, 1398,
Nov 2006.
T. Soygür, A. Akbay, and S. Küpeli, “Effect of potassium citrate therapy on stone recurrence and residual fragments after shockwave lithotripsy in lower caliceal calcium oxalate urolithiasis: a randomized controlled trial.,” J Endourology, vol. 16, no. 3, pp. 149–152, 2002, doi: 10.1089/089277902753716098.
M. Straub, W. L. Strohmaier, W. Berg, B. Beck, B. Hoppe, N. Laube, S. Lahme,
M. Schmidt, A. Hesse, und K. U. Koehrmann.
Diagnosis and metaphylaxis of stone disease. consensus concept of the
national working committee on stone disease for the upcoming german
urolithiasis guideline.
World J Urol, 23 (5): 309–323, Nov 2005.
S. Yallappa et al., “Natural History of Conservatively Managed Ureteral Stones: Analysis of 6600 Patients.,” Journal of endourology, vol. 32, no. 5, pp. 371–379, 2018.
Deutsche Version: Epidemiologie und Ursachen der Nephrolithiasis
Urology-Textbook.com – Choose the Ad-Free, Professional Resource
This website is designed for physicians and medical professionals. It presents diseases of the genital organs through detailed text and images. Some content may not be suitable for children or sensitive readers. Many illustrations are available exclusively to Steady members. Are you a physician and interested in supporting this project? Join Steady to unlock full access to all images and enjoy an ad-free experience. Try it free for 7 days—no obligation.
New release: The first edition of the Urology Textbook as an e-book—ideal for offline reading and quick reference. With over 1300 pages and hundreds of illustrations, it’s the perfect companion for residents and medical students. After your 7-day trial has ended, you will receive a download link for your exclusive e-book.




